How a reorganized Chapel Hill drug co. will take on the cardiology market

As Pozen (Nasdaq: POZN) turns to the next chapter as a company, it will look to hire a sales force and establish relationships with cardiologists. This will allow it to first sell the already approved drug Fibricor and set the table to sell Yosprala, which Pozen hopes will soon receive FDA approval. Since the beginning of June, the company has dropped some bombs. First, founder and longtime CEO John Plachetka retired, then it formed an Irish subsidiary, and finally acquired Canadian specialty pharmaceutical…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news